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Abstract 
The human amniotic membrane (HAM) is a highly abundant and readily available tissue. This amniotic tissue has 
considerable advantageous characteristics to be considered as an attractive material in the field of regenerative 
medicine. It has low immunogenicity, anti-inflammatory properties and their cells can be isolated without the 
sacrifice of human embryos. Since it is discarded post-partum it may be useful for regenerative medicine and cell 
therapy. Amniotic membranes have already been used extensively as biologic dressings in ophthalmic, abdominal 
and plastic surgery. HAM contains two cell types, from different embryological origins, which display some 
characteristic properties of stem cells. Human amnion epithelial cells (hAECs) are derived from the embryonic 
ectoderm, while human amnion mesenchymal stromal cells (hAMSCs) are derived from the embryonic mesoderm. 
Both populations have similar immunophenotype and multipotential for in vitro differentiation into the major 
mesodermal lineages, however they differ in cell yield. Therefore, HAM has been proposed as a good candidate to be 
used in cell therapy or regenerative medicine to treat damaged or diseased tissues. 
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1. Mesenchymal stem cell therapy as a new clinical approach to treat osteoarthritis 
Osteoarthritis (OA) is a degenerative joint disease characterized by deterioration in the integrity of 
hyaline cartilage and subchondral bone (Ishiguro et al., 2002). OA is the most common articular 
pathology and the most frequent cause of disability. Genetic, metabolic and physical factors interact in the 
pathogenesis of OA producing cartilage damage. The incidence of OA is directly related to age and is 
expected to increase along with the median age of the population (Brooks, 2002). 
The prevalence of OA in the human population underscores the importance of developing an effective 
and functional articular cartilage replacement. Recent research efforts have focused on tissue engineering 
as a promising approach for cartilage regeneration and repair (Kuo et al., 2006). Cartilage tissue 
engineering is critically dependent on the selection of appropriate cells, suitable scaffolds for cell delivery 
and biological stimulation with chondrogenically bioactive molecules (Kuo et al., 2006). 
Articular cartilage receives its nourishment through diffusion from the synovial fluid. The capacity for 
the self-repair of articular cartilage is very limited, mainly because it is an avascular tissue (Steinert et al., 
2007, Mankin, 1982, Resinger et al., 2004 and Fuentes-Boquete et al., 2008). Consequently, progenitor 
cells in blood and marrow cannot enter the damaged region to influence or contribute to the reparative 
process (Steinert et al., 2007). 
There are a lack of reliable techniques and methods to stimulate growth of new tissue to treat 
degenerative diseases and trauma (Wong et al., 2005). Currently, there are no effective pharmaceutical 
treatments for OA, although some medications slow its progression (Brandt and Mazzuca, 
2006 and Steinert et al., 2007). There are also no surgical approaches to treat OA; however, surgery is an 
important tool for the repair of cartilage injuries, which if left untreated may result in secondary OA. 
To date, most efforts made to repair an articular cartilage injury are intended to overcome the 
limitations of this tissue for healing by introducing new cells with chondrogenic capacity (Koga et al., 
2008) and facilitating access to the vascular system. Of the numerous treatments available nowadays, no 
technique has yet been able to consistently regenerate normal hyaline cartilage. Current treatments 
generate a fibrocartilaginous tissue that is different from hyaline articular cartilage. To avoid the need for 
prosthetic replacement, different cell treatments have been developed with the aim of forming a repair 
tissue with structural, biochemical and functional characteristics equivalent to those of natural articular 
cartilage. The overall objective is not only to heal the chondral defect (repair), but to generate new tissue 
identical to native articular cartilage in structure, biochemical composition and functional behavior 
(regeneration) (Fuentes-Boquete et al., 2007). 
Cell therapy is a new clinical approach for the repair of damaged tissues. Cell therapy using MSCs 
(Koga et al., 2008) or differentiated chondrocytes (autologous chondrocyte implantation, ACI) is one 
therapeutic option for the repair of focal lesions of articular cartilage, which is most successful in young 
people producing repair tissue of high quality (Brittberg et al., 1994 and Minas and Chiu, 2000). 
MSCs are multipotent non-hematopoietic progenitors located within the stroma of the bone marrow 
and other organs that are phenotypically characterized by the expression of several markers (e.g., CD73, 
CD90 and CD105) and the lack of expression of CD14 or CD11b, CD19 or CD79α, CD34, CD45 and 
HLA-DR surface molecules (Mrugala et al., 2009 and Kastrinaki et al., 2008). Moreover, characteristics 
of MSCs are also the expression of surface markers like Stro-1, CD44, CD73, CD90, CD105 and CD166 
(Pittenger et al., 1999). According to a recent proposal of the International Society for Cellular Therapy 
(Dominici et al., 2006) there are three criteria to define all types of stem cells: self-renewal, multipotency 
and the ability to reconstitute a tissue in vivo. Because there is no specific marker for MSCs, the principal 
criteria for identification are fibroblast-like morphology, adherence to the plastic of the tissue culture 
flask ( Prockop, 1997), the prolonged capacity for proliferation and the potential to differentiate in vitro 
into cells of mesodermal lineage. 
MSCs can be isolated by adherence to plastic, expanded ex vivo and induced, both in vitro or in vivo, 
to terminally differentiate into ectodermal (e.g., neurons) and endodermal (e.g., hepatocytes) lineages ( 
Pasquinelli et al., 2007) and also into cell of mesodermal origin (e.g., osteocytes, chondrocytes, 
adipocytes, tenocytes, myotubes, astrocytes and hematopoietic-supporting stroma) ( Barlow et al., 2008, 
Minguell et al., 2000 and Caplan, 1991). MSCs derived from bone marrow show a higher potential for 
osteogenic differentiation ( Muraglia et al., 2000), while MSCs of synovial origin show a greater 
tendency toward chondrogenic differentiation ( Djouad et al., 2005). Under identical culture conditions 
for differentiation, MSCs isolated from the synovial membrane show more chondrogenic potential than 
those derived from bone marrow, periostium, skeletal muscle or adipose tissue ( Sakaguchi et al., 2005). 
These results indicated that MSCs from different tissue sources can have biologic distinctions. Studies of 
cartilage injury repair in animal models using MSCs embedded in collagen gel ( Wakitani et al., 1989) or 
injected into defects closed with periosteal membrane ( Im et al., 2001) indicate that MSCs can 
differentiate in vivo into a number of cell types in different biologic environments. 
The recent use of autologous or allogenic stem cells has been suggested as an alternative therapeutic 
approach for treatment of cartilage defects (Jung et al., 2009). MSCs have the capability to self-renew and 
are responsible for repair and repopulation of damaged tissues in the adult (Hombach-Klonisch et al., 
2008, Pittenger, 2008 and Tsai et al., 2007). The use of autologous MSCs represents the advantage of 
avoiding the problem of immunological rejection of the allotransplant and the ethical conflict of using 
human embryonic stem cells (hESCs). Due to the low number of MSCs that can be isolated from a tissue 
biopsy, proliferation in vitro is necessary to obtain adequate cell numbers for their implant into the 
patient. Nevertheless, the number of mitotic divisions of MSCs in culture must be limited because MSCs 
age during in vitro culture, causing a reduction in their proliferative and multi-differentiation potential 
(Banfi et al., 2000, Bonab et al., 2006 and Izadpanah et al., 2006). The conservation of phenotype and 
differentiation capacity of MSCs is proportional to telomerization (Abdallah et al., 2005). Telomeres are 
normally shortened in successive cell divisions, however, in embryonic stem cells the telomere length is 
restored by telomerase enzyme activity. On the other hand, MSCs lack (Zimmermann et al., 2003) 
adequate levels of telomerase activity to achieve telomeric restoration (Izadpanah et al., 2006, Parsch et 
al., 2004 and Yanada et al., 2006). Patient age also influences the characteristics of MSCs because their 
proliferative capacity is reduced by aging (Stenderup et al., 2003). 
Human MSCs have been isolated from several tissues such as bone marrow (Kastrinaki et al., 
2008 and Yoo et al., 1998), articular cartilage (Alsalameh et al., 2004), synovial membrane (De Bari et 
al., 2001 and Fickert et al., 2003), perichondrium (Dounchis et al., 1997), periostium (Nakahara et al., 
1990), connective tissue of dermis and skeletal muscle (Young et al., 2001), adipose tissue (Zuk et al., 
2001 and Zuk et al., 2002), peripheral blood (Villaron et al., 2004, Kuznetsov et al., 2001 and Zvaifler et 
al., 2000), liver (Le Blanc et al., 2005), lung (In´tAnker et al., 2003), placenta (Barlow et al., 2008, 
Steigman and Fauza, 2007 and Fauza, 2004: Matikainen and Laine, 2005), umbilical cord (Baksh et al., 
2007, McGuckin et al., 2005 and Samuel et al., 2008), umbilical cord blood (Mareschi et al., 2001), 
amniotic fluid (You et al., 2008, Steigman and Fauza, 2007 and Fauza, 2004) and amniotic membrane 
(Díaz-Prado et al., 2010a, Díaz-Prado et al., 2010b and Alviano et al., 2007). Moreover, the list of tissues 
with the potential for tissue engineering is increasing because of recent progress in stem cell biology 
(Bianco and Robey, 2001). 
Although bone marrow is the traditionally used tissue source of adult MSCs, it has some limitations. 
Among the most important limitations are accessibility and that the procedure required to obtain this kind 
of tissue is invasive, painful and possibility of donor site morbidity, that the number of MSCs obtained is 
low, and that the potential to proliferate and differentiate diminishes as the donor´s age increases (Soncini 
et al., 2007, Baksh et al., 2007, Wei et al., 2009 and Ilancheran et al., 2009). The identification of 
alternative sources of MSCs would be beneficial for both research and therapeutic purposes. 
2. Structure of human amniotic membrane 
HAM develops from extra-embryonic tissue and consists of a fetal component, the chorionic plate and a 
maternal component, the deciduas, which are comprised of an epithelial monolayer, a thick basement 
membrane and an avascular stroma (Niknejad et al., 2008 and Jin et al., 2007). The amnion (Fig. 1) is a 
thin (up to 2 mm), elastic, translucent and semi-permeable fetal membrane attached to the chorionic 
membrane. Both the amnion and chorion form the amniotic sac filled with amniotic fluid, providing and 
protecting the fetal environment. The outer layer, the chorion, consists of trophoblastic chorionic and 
mesenchymal tissues. The inner layer, the amnion, consists of a single layer of ectodermally derived 
epithelium uniformly arranged on the basement membrane, which is one of the thickest membranes found 
in any human tissue, and a collagen-rich mesenchymal layer (Wilshaw et al., 2006). This mesenchymal 
layer can be subdivided into the compact layer forming the main fibrous skeleton of the HAM, the 
fibroblast layer and an intermediate layer, which is also called the spongy layer or zona spongiosa ( 
Niknejad, et al. 2008). 
 
 
 
Fig. 1. Structure of the HAM. HAM was stained with HE, hematoxylin and eosin. AE: Amniotic epithelium; ★: Basement 
membrane; ⊙: Compact layer; : Fibroblastic layer and SL: Spongy Layer or zona spongiosa. 
  
3. Potential applications of human amniotic membrane 
Recent studies have focused on tissue engineering as a promising approach for cartilage regeneration 
(Kuo et al., 2006). Cartilage tissue engineering is based on the selection of appropriate cells, suitable 
scaffolds and stimulation with chondrogenic molecules (Kuo et al., 2006). Both natural and synthetic 
polymers have been fabricated for cartilage tissue engineering, such as fibrous structures, porous sponges, 
woven or non-woven meshes and hydrogels (Tritz et al., 2010, Yuan et al., 2010 and Kuo et al., 2006). 
In cartilage tissue engineering, recent studies have focused not only on appropriate cells but also on 
novel methods of manufacture allowing building stratified scaffolds. In this regard, Han et al. (2008) 
established and validated a molding technique for fabrication of cartilaginous constructs that are 
anatomically shaped on one or two surfaces, targeting the spherically shaped hip and biomimetically 
stratified with superficial and middle/deep zone chondrocyte subpopulations. On the other hand, Tritz et 
al. (2010) aimed to buildup complex biomaterials for reconstructing biological tissue with three 
dimensional cells construction for mimicking cartilage architecture. These authors published for the first 
time that is possible to spray mixed alginate and chondrocytes with little damage for cells. Therefore, the 
sprayed hydrogel keeps not only the mechanical properties needed for cells, but also maintains the 
chondrocyte phenotype to induce cartilage. 
HAM has some characteristics that highlight their clinical use as scaffold compared to other 
biocompatible products. In this regard HAM is anti-microbial, anti-tumorigenic, anti-fibrosis, anti-
angiogenic and has acceptable mechanical properties. It also reduces pain and inflammation, inhibits 
scarring, shows little or no immunogenicity thus it does not represent transplantation risks, enhances 
wound healing and epithelialization and acts as an anatomical and vapor barrier (Dua et al., 2004, 
Ganatra, 2003, Gomes et al., 2005 and Hao et al., 2000). In vitro studies have demonstrated that cells 
isolated from amnion do not trigger immuno allogenic or xenogenic responses, actively suppress the 
proliferation of T lymphocytes and inhibit the differentiation of monocytes. The HAM survives for long 
periods in immunocompetent animals and the cells are grafted persistently in various organs and tissues. 
Amnion expresses the non-classic and little polymorphic HLA-G molecules (class I b) and lacks the 
highly polymorphic antigens HLA A-B-C- (class I a), HLA DR (class II) and the T cell co-stimulatory 
molecule B-7. The HLA-G molecule displays at least four inhibitory functions relevant to immune 
responses (Insausti et al., 2010): (a) it can bind directly to inhibitory receptors found in NK cells and 
other leukocytes. (b) It possesses the appropriate leader peptide for binding to HLA-e, which will in turn 
inhibit the NK cells via their CD94/NKg2 receptor. (c) It can induce apoptosis of activated CD8+ T cell. 
(d) It can inhibit CD4+ T cell proliferation. Moreover, in mixed lymphocyte reactions using allogeneic 
cells, hAECs and hAMSCs, do not induce a cytotoxic response and inhibits lymphocyte proliferation 
(Ilancheran et al., 2009). 
These properties enable surgeons to apply the HAM graft on various tissue surfaces without suturing. 
HAMs have been used as biologic dressings for ophthalmology, plastic surgery, dermatology and 
gynecology procedures (Tejwani et al., 2007, Santos et al., 2005, Harijadi et al., 2006, Meller et al., 
2000 and Morton and Dewhurst, 1986). Moreover, the extracellular matrix (ECM) of the HAM has 
several components such as laminin, different types of collagens (I, III, IV, V and VI), nidogen, 
fibronectin, growth factors, hyaluronan and proteoglycans (Niknejad et al., 2008, Harijadi et al., 
2006 and Jin et al., 2007) that are abundant on natural cartilage and are responsible of regulation and 
maintenance of normal chondrocyte metabolism (Jin et al., 2007); suggesting their use for cartilage tissue 
engineering (Niknejad et al., 2008). Indeed, a recent report showed the utility of the HAM as a scaffold to 
support human chondrocyte proliferation in cell therapy to repair human OA cartilage (Díaz-Prado et al., 
2010c) (Fig. 2). The low cost of HAM graft preparation and the very good clinical results in different 
applications have proposed the amnion as an alternative to other natural and synthetic wound dressings. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. In vitro repair model of human OA articular cartilage. Human articular chondrocytes grown over HAM provided a 
superficial cell cover that decreased the degree of damages of the OA articular cartilage surface (A, B, C and G). The newly-formed 
tissue showed high cell density and a thickening of the basement membrane of the HAM (D). Type I (E) and type II (F) collagen 
immunostainings indicated the fibrocartilaginous nature of the newly synthesized tissue. HE, hematoxylin and eosin; MM, Masson´s 
trichrome; Col I, type I collagen; Col II, type II collagen. Original magnifications: (A), (B) and (D) 200×; (C), (E), (F) and (G) 
100×. 
Published data suggest that HAM is a very attractive source of MSCs. Since the amniotic membrane 
arises from embryonic epiblast cells prior to gastrulation, it has been suggested that it may retain a 
reservoir of stem cells throughout pregnancy (Ilancheran et al., 2007). Pre-clinical and clinical studies 
have demonstrated multiple uses for amniotic membrane stem cells in tissue repair, such as corneal tissue 
(Shimmura and Tsubota, 2002), spinal cord injury (Sankar and Muthusamy, 2003), brain infarction 
(Sakuragawa et al., 1997) and Parkinson´s disease (Kakishita et al., 2003). Bailo et al. (2004) isolated and 
characterized amniotic and chorionic cells from human full-term placentas, which suggested that both cell 
types may represent an advantageous source of progenitor cells. Indeed, the HAM is becoming 
appreciated as an alternative to bone marrow for adult MSCs for regenerative medicine. 
Because fetal tissues are routinely discarded post-partum, HAMs have proved to be abundant, 
inexpensive and easily obtained with a virtually limitless availability, negating any need for mass tissue 
banking (Chang et al., 2010, Toda et al., 2007, Niknejad et al., 2008, Hennerbichler et al., 
2007 and Wilshaw et al., 2006). Moreover, this tissue provides efficiency in MSC recovery with non-
invasive and safe procedures (Alviano et al., 2007). A major advantage of cells isolated from the HAM is 
that they are harvested after birth and can be cryogenically stored to be available in a timely manner for 
patient therapy after being thawed and expanded for use in tissue engineering, cell transplantation and 
gene therapy. Therefore, the HAM represents a very useful source of progenitor cells for a variety of 
applications. Because human embryos are not sacrificed for the isolation of progenitor cells from HAMs, 
the current controversies associated with the use of human embryonic stem cells can be avoided (Chang 
et al., 2010, Insausti et al., 2010, Toda et al., 2007 and Kim et al., 2009). 
This fetal tissue expresses only moderate levels of the major histocompatibility complex (MHC) class 
I and MHC class II antigens on its surface. Therefore, hAECs and hAMSCs seem to be immune-
privileged; thus, suitable for allo-transplantation and regenerative medicine (Wei et al., 2009 and Kim et 
al., 2009). 
In the present review, we focused the localization, isolation, quantification and phenotypic 
characterization of HAM-derived cells (hAECs and hAMSCs) and summarized their in vitro 
differentiation potential useful for regenerative medicine and cell therapy. 
4. Localization of human amniotic membrane-derived cells 
Location of HAM-derived cells in healthy human amniotic membranes stained with hematoxylin-eosin or 
Masson´s Trichrome may be studied by histochemical and immunohistochemical techniques. The HAM 
contains two different cell types, hAECs and hAMSCs, from different embryological origins (Alviano et 
al., 2007 and Wolbank et al., 2007). The hAECs forms a continuous monolayer of embryonic 
ectodermally derived epithelium uniformely arranged on the basement membrane (BM) in contact with 
the amniotic fluid (Tamagawa et al., 2008) (Fig. 3A and B). The hAECs are positive for the epithelial 
markers cytokeratin 1, 2, 3, 4, 5, 6, 7, 8, 10, 13, 14, 15, 16 and 19 (Díaz-Prado et al., 2010a) (Fig. 3C), 
which confirms its epithelial nature. BM is one of the thickest membranes found in any human tissue that 
contains different types of collagens (Fig. 3D), fibronectin, nidogen, laminin, proteoglycans and 
hyaluronan, as well as growth factors (Niknejad et al., 2008, Harijadi et al., 2006 and Jin et al., 2007). 
hAMSCs are derived from embryonic mesoderm (Tamagawa et al., 2008) and are sparsely distributed in 
the stroma underlying the amnion epithelium (Bilic et al., 2008). An immunofluorescence study 
demonstrated that BM contains hAMSCs since they express common and well defined human MSC 
markers previously described for bone marrow MSCs such as CD44, CD90, CD105 and CD271 
indicating that BM contains cell having stem-cell characteristics (Fig. 3E). The same study corroborated 
that hAECs contain positive cells for MSCs markers such as CD105 (Díaz-Prado et al., 2010b), indicating 
that the HAM contains at least two different cell types having stem-cell characteristics. 
 
 
 
Fig. 3. Histological characterization of human amnion-derived cells. Sections of healthy HAM stained with H-E (A) and MM (B), 
immunohistochemistry for CK (C) and Col II (D) and by immunofluorescence for CD90 and CD105 (E). In (E) nuclei were 
counterstained with 4',6-diamidino-2-phenylindole (DAPI). BM indicates the thick basement membrane, and EC, the epithelial cells 
from extra-embryonic ectoderm. CK, cytokeratins. Original magnifications: (A) 100×, (B) 400×, (C–E) 200×. 
5. Isolation and cultivation of cells from human amniotic membrane 
Cells from the mesenchymal and epithelial regions of the amnion can be isolated easily. Different 
methods to isolate HAM-derived cells have been published (Dazzi and Marelli-Berg, 2008, Parolini et al., 
2008, Alviano et al., 2007, Soncini et al., 2007, Miki et al., 2007a, Miki and Strom, 2006 and Bailo et al., 
2004). All of them start with a mechanical separation of the amniotic membrane from the underlying 
chorion through the spongy layer (Insausti et al., 2010), followed by a digestion with trypsin, dispase or 
other digestive enzymes, in different concentrations and for different periods of time, to release the 
hAECs from the basal membrane. hAMSCs can be subsequently released through subsequent digestion 
with collagenase (Parolini et al., 2009), alone or combined with DNAase (Steigman and Fauza, 2007). 
hAECs are small-size cells that are easy to expand in vitro for at least 3 passages without morphological 
changes, they grow in a lattice and have the typical cuboid morphology of epithelial cells (Fig. 4A). 
These cells generally have a central or eccentric nucleus, one or two nucleoli and abundant cytoplasm, 
usually vacuolated (Miki et al., 2007a). The hAMSCs cells have fibroblast-like cell morphology (Fig. 4B) 
and after 3 to 4 weeks of culture it is possible to obtain a population of adherent mesenchymal cells 
morphologically identical to MSCs isolated from bone marrow. These stromal cells are easy to expand in 
vitro for at least 9 passages without morphological changes. hAECs and hAMSCs can be grown in 
Dulbecco modified Eagle´s media (DMEM) supplemented with 20% fetal bovine serum (FBS) and 1% 
penicillin–streptomycin (P/E) and seeded into culture flasks. Both populations should be expanded in a 
humidified 5% CO2 atmosphere at 37 °C. After the isolation of both cell types it is advisable to perform 
immunohistochemical stainings (e.g. for cytokeratin 7, CK7) to demonstrate the purity of both 
populations. In this regard, only hAECs may be positive for this or other epithelial markers (Fig. 5). A 
recent study (Díaz-Prado et al., 2010a) compared two previously published protocols for the isolation of 
hAMSCs (Soncini et al., 2007 and Alviano et al., 2007), including their phenotypic characterization and 
in vitro potential for differentiation toward osteogenic, adipogenic and chondrogenic mesodermal 
lineages. Both protocols resulted in the isolation and culture of cells attached to the culture flask with 
fibroblast-like cell morphology. Quantitative studies showed that Soncini´s protocol typically showed an 
increase in the hAMSCs isolation yield of almost ten fold with regard to Alviano´s protocol. Also, the 
former protocol allowed the isolation and expansion of a larger number of cells in a very short time 
period. This ready and rapid availability of cells is one criteria required of a source of MSCs for it to be 
considered for cell transplantation. 
 
 
 
Fig. 4. Morphology of cultured hAECs (A) and hAMSCs (B) isolated from human amniotic membrane. Original magnifications: 
100×. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. Immunohistochemical stainings for CK7 expression in cultured HAECs (A) and hAMSCs (B). Original magnifications: 
400×. 
There is a contradiction with the passage number at which HAM-derived cells stop proliferation. 
Based on the literature, proliferation slows down with every passage and cells settle into senescence until 
proliferation ceases. For example, Miki et al. (2007a) and Parolini et al. (2008) state that hAECs grow 
normally for 2 to 6 passages before proliferation ceases. On the contrary Bilic et al. (2008) confirmed that 
hAECs and hAMSCs proliferation almost stops beyond passage 5 whereas Toda et al. (2007) postulated 
that hAECs senescence is reached at lower passages, P3 or P4. However Alviano et al. (2007) and 
Soncini et al. (2007) indicated that hAMSCs are easily expanded in vitro for at least 15 passages without 
any visible morphological alterations but they used cells not exceeding P4 for cell characterization and 
multilineage differentiation potential studies. 
A comparison between placental cells and bone marrow-derived mesenchymal stem cells (BM-MSCs) 
was the aim of the paper published by Barlow et al. (2008). These authors compared human placenta-
derived MSCs (the placental tissue included amnion, chorion and decidua) and human bone marrow-
derived MSC in terms of cell characteristics, optimal growth conditions, mesodermal lineage 
differentiation and in vivo safety specifically to determine if human placenta-derived MSCs could 
represent a source of human MSC for clinical trials. They demonstrated that both populations were 
similar in terms of growth condition requirements and in terms of subsequent biological characterization. 
However both populations differed with respect to their proliferation capabilities at different seeding 
densities. In this regard human bone marrow-derived MSCs proliferated more slowly than human 
placenta-derived MSCs in every experiment. Also the latter had greater long-term growth ability than the 
former. Moreover MSCs from both sources exhibited similar morphology, size and cell surface phenotype 
and mesodermal differentiation ability with the exception that human placenta-derived MSC consistently 
appeared less able to differentiate to the adipogenic lineage. In line with the results obtained these authors 
suggested that human placenta is an acceptable alternative source for human MSC. 
6. Characterization of cells isolated from human amniotic membrane 
Immunophenotypic characterization of hAMSCs demonstrate the presence of the common well defined 
human MSC markers (CD90, CD44, CD73, CD166, CD105 and CD29), described for bone marrow with 
the absence of the hematopoietic markers (CD34 and CD45) and the concomitant lack of monocyte 
(CD114), macrophage (CD11) and fibroblast markers (Insausti et al., 2010, Kobayashi et al., 
2008 and Mihu et al., 2009). This antigen expression pattern is consistent with data published for stem 
cells isolated from various regions of the full-term placenta (Bilic et al., 2008, Bailo et al., 2004, 
Kobayashi et al., 2008, Barlow et al., 2008 and Mihu et al., 2009). hAMSCs also express low levels of 
HLA-ABC, but do not express HLA-DR, indicating that these stromal cells may be useful in clinical 
transplantation procedures (Parolini et al., 2009). 
hAECs are positive for desmin and vimentin (Toda et al., 2007) and also for the same markers as 
hAMSCs (Díaz-Prado et al., 2010b). Therefore hAECs also had an antigen expression profile 
characteristic of culture-expanded MSCs (Bilic et al., 2008). Phenotypes of both cell populations, hAECs 
and hAMSCs, are maintained from passage P0 through passage P9 (Díaz-Prado et al., 2010b). It is 
important to note that in culture although both populations show and maintain a similar marker profile for 
mesenchymal progenitors there are many differences between them in cell shape and cell arrangement 
(Díaz-Prado et al., 2010b and Bilic et al., 2008). 
Ilancheran et al. (2007) showed that hAECs expressed surface markers that are normally present on 
embryonic stem and germ cells such as SSEA3 (stage specific embryonic antigen 3), SSEA4, TRA-1-60 
(tumor rejection antigen) and TRA-1-81 and other antigens such as the ABCG 2/BCRP (a member of the 
ATP-binding cassette superfamily), CD9, CD24, E-Cadherin, Integrin α6 and β and c-met (receptor 
growth factor of the hepatocyte) (Niknejad et al., 2008 and Insausti et al., 2010). These epithelial cells 
also express transcription factors specific for pluripotential stem cells such as Oct4 (octamer binding 
protein 4), NANOG, SOX2 (SRY-related HMG-box gene 2) and REX-1 (Parolini et al., 2009, Miki et al., 
2007b, Miki et al., 2005 and Miki and Strom, 2006). hAMSCs are also positive for these pluripotency 
markers but positivity for embryonic stem cell markers, SSEA-3 or SSEA-4, remains debated (Parolini et 
al., 2009). 
Parolini et al. (2009) published a comparison of key features of human amniotic membrane-derived 
cells and human BM-MSCs (Table 1). These authors postulated that BM-MSCs have a higher cell 
doubling time that hAECs, while for the hAMSC this time was not reported yet. Regarding the maximum 
number of passages it ranges from 5 to 10 for hAMSCs, 10 to 20 for BM-MSCs and 30 for hAECs. In 
vitro differentiation potential toward endodermal, mesodermal and ectodermal lineages was also reported 
for the three cell types. 
Table 1. Comparison of cell doubling time, maximum numbers of passages and differentiation potential of hAECs, hAMSCs and 
BM-MSCs. Data taken from Parolini et al. (2009). 
Cell type Cell doubling time 
Maximum number of 
passages 
Differentiation potential 
    
hAECs 
At 5th passage: 
24 h. 
30 
In vitro differentiation toward endodermal, mesodermal and 
ectodermal lineages. 
 
At 30th passage: 
18 h. 
  
hAMSCs Not reported. 5–10 
In vitro differentiation toward endodermal, mesodermal and 
ectodermal lineages. 
BM-MSCs 36–72 h. 10–20 
In vitro differentiation toward endodermal, mesodermal and 
ectodermal lineages. 
    
 
7. Differentiation potential of amniotic cells 
The pluripotency of hAECs was supported by a study by Tamagawa et al. (2004). These scientific created 
a xenogeneic chimera with hAECs and mouse embryonic stem cells in vitro. This chimera gives rise to 
cells of all germ layers. Later studies have corroborated the ability of hAECs to in vitro differentiate into 
cells from the three germ layers (Insausti et al., 2010, Ilancheran et al., 2007 and Miki et al., 2005). 
hAECs have characteristics of neural progenitor cells since these epithelial cells express some 
differentiation markers for neural stem, neuron and glial cells such as nestine, GAD (glutamate 
decarboxylase), GFAP (glial fibrillary acidic protein) and CNP (cyclic nucleotide phosphodiesterase) 
(Miki et al., 2005). Elwan and Sakuragawa (1997) and Kakishita et al. (2000), demonstrated the 
differentiation of the epithelial cells to neural cells (ectodermal lineage) with capacity to synthesize and 
release acetylcholine, catecholamines and dopamine, suggesting their possible utility in the treatment of 
neural degenerative diseases. In this regard, several studies have already been published showing 
promising results in animal models with Parkinson´s disease and Mucopolysaccaridosis type VII. Studies 
of intracerebral grafting of hAECs for the treatment of a mouse model of Parkinson´s disease showed that 
these epithelial cells can synthesize and release catecholamine and neurotrophic factors such as nerve 
growth factor, neurotrophin-3 and brain-derived neurotrophic factor (Kakishita et al., 2003, Kakishita et 
al., 2000 and Uchida et al., 2000). Kosuga et al. (2000) suggested that transplantation of hAECs 
transduced with adenoviral vectors can be employed for the treatment of congenital lysosomal storage 
disorders. 
Hepatic differentiation (endodermal lineage) of hAECs was also reported by Sakuragawa et al. (2000). 
These authors demonstrated that cultivated hAECs produced albumin and α-fetoprotein; and that 
hepatocyte-like cells, positive for albumin and α-fetoprotein, could be identified integrated in the liver 
parenchyma of mice with severe combined immunodeficiency (SCID), after the transplantation of hAECs 
in the liver. Later studies demonstrated that these epithelial cells also displayed other functional properties 
associated with hepatocytes, such as glycogen storage and expression liver-enriched transcription factors, 
such as hepatocyte nuclear factor (HNF) 3γ and HNF4α, CCAAT/enhancer-binding protein (CEBP α and 
β) and several of the drug metabolizing genes (cytochrome P450) (Miki et al., 2005, Takashima et al., 
2004 and Davila et al., 2004). These findings suggest the potential utility of hAECs for restore hepatic 
tissues that have been diseased or injured. Differentiation of hAECs to another endodermal lineage, 
pancreatic, was also reported. Wei et al. (2003) cultured these epithelial cells in the presence of 
nicotinamide to induce pancreatic differentiation and they observed that the resulting cells expressed 
insulin. Subsequent transplantation of these insulin-expressing cells in the spleen of diabetic SCID mice 
normalized the levels of serum glucose for several months after the transplant, indicating the therapeutic 
potential of hAECs to treat diabetes mellitus type I. Later, Miki et al. (2005) showed by RT-PCR analysis 
that, after pancreatic differentiation, hAECs express pancreatic α and β cell markers such as the 
transcription factors PDX-1 (pancreatic duodenum homeobox 1), PAX-6 (paired box homeotic gene 6) 
and NKX2.2 (NK2 transcription factor-related locus 2) and the mature hormones insulin and glucagon. 
The differentiation of hAECs to cardiac cells (mesodermal lineage) was first evaluated by Miki et al. 
(2005). They demonstrated by RT-PCR that cardiac-specific genes atrial and ventricular myosin light 
chain 2 (MLC-2A and MLC-2V) and the transcription factors GATA-4 and Nkx 2.5 are expressed or 
induced in hAECs cultured in media supplemented with ascorbic acid for 14 days. The 
immunohistochemical analysis of alpha-actinin expression showed a staining pattern very similar to the 
one reported for hESC-derived cardiomyocytes. Differentiation of hAECs to another mesodermal 
lineages (Fig. 6 and Fig. 7) was reported by Ilancheran et al. (2007), who showed that native hAECs can 
differentiate into cells with a phenotype and markers characteristic of mesodermal-derived myocytes, 
osteocytes and adipocytes. 
 
 
 
Fig. 6. Osteogenic (DIF Osteo) and adipogenic (DIF Adipo) differentiation of human amnion mesenchymal stromal cells (hAMSCs) 
and human amnion epithelial cells (hAECs) with their respective controls (C hAMSC and C hAEC) grown for 21 days in 
Dulbecco's Modified Eagle Medium (DMEM 21). The presence of the calcium deposits characteristic of osteoblasts was detected 
using Alizarin Red (AR) stain (A). The presence of adipocytes was assessed by detection of lipid drops using Oil Red O (OR-O) 
stain (B). Original magnifications: 400×. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7. Chondrogenic differentiation, assessed by micropellet formation, of hAMSCs [A] and hAECs [B]. Original magnifications: 
200x. 
MSCs from different parts of the placenta have been shown to differentiate into chondrogenic, 
osteogenic, endothelial, hepatocytic, myogenic and neurogenic lineages, but with appreciable differences 
among cell types depending on the placental tissue source (Chang et al., 2010, Insausti et al., 2010, 
Portmann-Lanz et al., 2006, Tamagawa et al., 2007, Tamagawa et al., 2008, Kobayashi et al., 2008, In´t 
Anker et al., 2004, Alviano et al., 2007, Wei et al., 2009, Mihu et al., 2009, Pasquinelli et al., 2007, 
Soncini et al., 2007 and Sakuragawa et al., 2004). 
hAMSCs differentiation to neuronal lineage have been demonstrated by the fact that these cells 
express neuronal markers (Nestin, Musashi 1, neuron-specific enolase, neurofilament medium, 
microtubule-associated protein [MAP]-2 and Neu-N) and glial (GFAP) markers, after their culture in 
specific neural-induction media (Sakuragawa et al., 2004, Portmann-Lanz et al., 2006, Kim et al., 
2007 and Tamagawa et al., 2008). 
Tamagawa et al. (2007) showed that hAMSCs were able to differentiate into cells with characteristics 
of hepatocytes. In this regard, native cells expressed typical hepatocytic mRNA such as albumin, CK 
(cytokeratin) 18, α-fetoprotein, α 1-antitrypsin and HNF-4α but only glucose-6-phosphatase and ornithine 
transcarbamylase expression and glycogen storage were observed after in vitro hepatic induction. 
Regarding hAMSCs differentiation towards mesodermal lineage (Fig. 6 and Fig. 7), In´tAnker et al. 
(2004) demonstrated the potential of hAMSCs to differentiate into osteogenic and adipogenic cells. After 
osteogenic differentiation hAMSCs suffered morphologic changes and showed calcium deposits when 
they were stained with von Kossa´s dye. On the other hand, after adipogenic differentiation hAMSCs 
become multi vacuolated cells that were stained with Red oil O stain. Later, Portmann-Lanz et al. (2006) 
showed the capacity of these stromal cells for differentiation to chondrogenic and myogenic lineages. 
Chondrogenic differentiation of these cells was demonstrated by the presence of abundant collagen in the 
extracellular matrix by means of Alcino´s blue dye. Myogenic differentiation of hAMSCs has been 
determined by RT-PCR since Portmann-Lanz et al. (2006) demonstrated the mRNA expression of 
myogenic transcription factors such as Myo D and Myogenin and the protein expression of desmine in 
hAMSCs cultured in differentiation media. Alviano et al. (2007) confirmed these results and also was the 
first in demonstrate the angiogenic differentiation potential of these cells. This latter study revealed that 
hAMSCs, after culture in induction media with VEGF, expressed endothelial-specific markers such as the 
receptors of the vascular endothelial growth factor 1 and 2 (FLT-1, KDR), ICAM-1 as well as the 
appearance of CD34 and von Willebrand Factor (vWF) positive cells. Regarding cardiomyogenic 
potential, it has been demonstrated that hAMSCs expressed cardiac-specific genes such as GATA4, 
MLC-2a (myosin light chain), MLC-2v, cTnI and cTnT (Tanaka et al., 1999 and Zhao et al., 2005) after 
cardiomyogenic induction. Zhao et al. (2005) showed that after hAMSCs transplantation into the 
myocardial infarcts in rat hearts, these cells survived in the scar tissue for at least 2 months and 
differentiated into cardiomyocyte-like cells. On the other hand, spontaneous differentiation of hAMSCs 
towards myofibroblasts has also been observed after their culture in standard medium (DMEM/FBS) 
within 2 passages (Li et al., 2008)  
8. Summary 
HAM, an abundant, inexpensive and easily obtained tissue that is discarded post-partum, represents a 
valuable material for tissue banking and a viable alternative to other synthetic or natural scaffolds. 
Amnion contains two different cell types, hAECs and hAMSCs, which display characteristic properties of 
stem cells. Both amnion-derived populations are easily isolated from HAM and have the capacity to 
differentiate in vitro into all three germ layers: endoderm, mesoderm and ectoderm, suggesting their great 
interest in the fields of cell therapy and regenerative medicine. The unlimited availability of HAMs, the 
high efficiency in MSC recovery with non-invasive and safe procedures, the minimal ethical and legal 
issues associated with its use and the low immunogenicity of amnion-derived cells, make them an 
alternative source of MSCs. More studies should be carried out to determine whether such in vitro-
differentiated cells can function in vivo. 
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